In this study, we further investigated whether ZD55-IL-24 therapy in combination with PD-1 immune checkpoint inhibition could facilitate primary tumor as well as metastatic lesions rejection in B16-bearing immunocompetent mouse model. Here, PDCD1 is linked to neoplasm.